EFFECTS OF THE PROTON PUMP INHIBITOR, E3810, ON GASTRIC-SECRETION AND GASTRIC AND DUODENAL-ULCERS OR EROSIONS IN RATS

被引：22

作者：

FUJISAKI, H

SHIBATA, H

OKETANI, K

MURAKAMI, M

FUJIMOTO, M

WAKABAYASHI, T

YAMATSU, I

TAKEGUCHI, N

机构：

[1] Tsukuba Research Laboratories, Eisai Co. Ltd, Tsukuba, 300-26

[2] Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Toyama

来源：

DRUG INVESTIGATION | 1991年 / 3卷 / 05期

关键词：

D O I：

10.1007/BF03259747

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The effects of E3810, a potent proton pump inhibitor, on gastric secretion and gastric or duodenal ulcers or erosions were studied in rats. Intraduodenal administration of E3810 dose dependently inhibited gastric secretion (volume and acid outputs) in pylorus-ligated rats. The effective dose required to inhibit volume output by 50% (ED50) was 12 mg/kg and that for acid output was 3.4 mg/kg. Acutely induced gastric ulcers or erosions, such as cold-restraint stress erosions, Shay ulcers and mercaptamine (cysteamine)-induced duodenal ulcers, were significantly inhibited by oral, intraduodenal or subcutaneous administration of E3810 at 1 to 100 mg/kg. The protective effects of E3810 in these acute models were compared with those of omeprazole at the same doses. At low doses, 10 mg/kg (intraduodenally) in Shay ulcers and 3 mg/kg (subcutaneously) in mercaptamine-induced ulcers, E3810 was significantly more effective than omeprazole. But at high doses, there was no significant difference between the 2 drugs in efficacy. In the cold stress erosion model, the drugs were equally effective.

引用

页码：328 / 332

页数：5

共 17 条

[1]

Bader J-P, Opening address, Scandinavian Journal of Gastroenterology, 24, pp. 1-2, (1989)

[2]

Figala V., Klemm K., Kohl B., Kruger U., Rainer G., Et al., Acid activation of H++K+-ATPase inhibiting 2-(2-pyridyl-methyl-sulfinyl)-benzimidazoles: isolation and characterisation of the thiophilic ‘active principle’ and its reactions, Journal of the Chemical Society. Chemical Communications, pp. 125-127, (1986)

[3]

Fujii Y., Ishii Y., Influence of various factors and drugs on cysteamine-induced duodenal ulcers in the rat, Japanese Journal of Pharmacology, 25, pp. 663-670, (1975)

[4]

Fujisaki H., Shibata H., Oketani K., Murakami M., Fujimoto M., Et al., Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione, Biochemical Pharmacology, 42, pp. 321-328, (1991)

[5]

Herling A.W., Bickel M., Lang H-J, Weidmann K., Rosner M., Et al., A substituted thieno[3,4-d]-imidazole versus substituted benimidazoles as H+ K+-ATPase inhibitors, Pharmacology, 36, pp. 289-297, (1988)

[6]

Konturek S.J., Brzozowski T., Radecki T., Protective action of omeprazole, a benzimidazole derivative, on gastric mucosal damage by aspirin and ethanol in rats, Digestion, 27, pp. 159-164, (1983)

[7]

Lindberg P., Nordberg P., Alminger T., Brandstrom A., Wallmark B., The mechanism of action of the gastric acid secretion inhibitor omeprazole, Journal of Medicinal Chemistry, 29, pp. 1327-1329, (1986)

[8]

Long J.F., Chiu J.S., Derelanko M.J., Steinberg M., Gastric antisecretory and cytoprotective activities of SCH 28080, Journal of Pharmacology and Experimental Therapeutics, 226, pp. 114-120, (1983)

[9]

Mattsson H., Andersson K., Larsson H., Omeprazole provides protection against experimentally induced gastric mucosal lesions, European Journal of Pharmacology, 91, pp. 111-114, (1983)

[10]

Morii M., Takata H., Takeguchi N., Acid activation of omeprazole in isolated gastric vesicles, oxyntic cells, and gastric glands, Gastroenterology, 96, pp. 1453-1461, (1989)

← 1 2 →